

MARKET REPORT



Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

“Growing number of cross-industry collaborations and partnerships and the need to control drug discovery & development costs and reduce the overall time taken in this process are the key factors driving the AI in the drug discovery market.”

The global AI in the drug discovery market is projected to reach USD 1,434 million by 2024 from USD 259 million in 2019, at a CAGR of 40.8% during the forecast period. Growth in this market is mainly driven by growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiry of blockbuster drugs. On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

“The immuno-oncology segment accounted for the largest share in 2019.”

Based on application, the artificial intelligence in the drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of 44.6% of the AI in the drug discovery market in 2018, owing to the increasing demand for effective cancer drugs. Neurodegenerative diseases form the fastest-growing application segment, with a CAGR of 42.9% during the forecast period. The ability of AI to discover drugs for complex diseases and the emphasis of market players on providing AI-based platforms for neurological diseases are responsible for the fast growth of this application segment.

“The Research centers and academic & government institutes segment to register the highest growth rate in the forecast period.”

Based on end-user, the AI in the drug discovery market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and research centers and academic, & government institutes. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in the drug discovery market. AI and machine learning to allow pharmaceutical companies to operate more efficiently and substantially improve success rates at the early stages of drug development. This is one of the major factors driving the growth of this market. Research centers and academic & government institutes are expected to show the highest growth of 43.6%. during the forecast period. The growth of the CROs segment is tied to that of pharmaceutical & biotechnology companies, as the rise in research and production activity will ensure sustained demand for contract services.

“North America to be the largest and the fastest-growing regional market.”

North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. In the North American market, the US is a significant contributor. Also, prominent AI technology providers, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their strong presence is a key contributor to

market growth. Other drivers include the well-established pharmaceutical industry, high focus on R&D & substantial investment, and the presence of globally leading pharmaceutical companies. These are some of the major factors responsible for the large share and high growth rate of this market.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 (28%), Tier 2 (42%), and Tier 3 (30%)
- By Designation: C-level (30%), D-level (34%), and Others (36%)
- By Region: North America (46%), Europe (25%), Asia (18%), and the RoW (11%)

List of Companies Profiled in the Report

- IBM Corporation (US)
- Microsoft (US), Google (US)
- NVIDIA Corporation (US)
- Atomwise, Inc. (US)
- Deep Genomics (Canada)
- Cloud Pharmaceuticals (US)
- Insilico Medicine (US)
- Benevolent AI (UK)
- Exscientia (UK)
- Cyclica (Canada)
- BIOAGE (US)
- Numerate (US)
- Numedii (US)
- Envisagenics (US)
- twoXAR (US)
- OWKIN, Inc. (US)
- XtalPi (US)
- Verge Genomics (US)
- Berg LLC (US)

Research Coverage:

This report provides a study of the AI in the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments, such as offering, technology, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall AI in drug discovery market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Additional Details

Publisher : MarketsandMarkets

Reference : HIT 7445

Number of Pages : 156

Report Format : PDF

Publisher Information :



BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

MARKETSANDMARKETS

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

- TABLE OF CONTENTS1 INTRODUCTION 171.1 OBJECTIVES OF THE STUDY 171.2 MARKET DEFINITION 171.3 MARKET SCOPE 181.3.1 MARKETS COVERED 181.3.2 YEARS CONSIDERED FOR THE STUDY 191.4 CURRENCY 191.5 LIMITATIONS 191.6 STAKEHOLDERS 202 RESEARCH METHODOLOGY 212.1 RESEARCH DATA 212.1.1 SECONDARY SOURCES 222.1.1.1 Key data from secondary sources 232.1.2 PRIMARY SOURCES 232.1.2.1 Key data from primary sources 242.1.2.2 Key industry insights 252.2 MARKET SIZE ESTIMATION 262.3 MARKET BREAKDOWN AND DATA TRIANGULATION 282.4 ASSUMPTIONS FOR THE STUDY 293 EXECUTIVE SUMMARY 304 PREMIUM INSIGHTS 354.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 354.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2019–2024) 364.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2018) 374.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 385 MARKET OVERVIEW 395.1 INTRODUCTION 395.2 MARKET DYNAMICS 395.2.1 MARKET DRIVERS 405.2.1.1 Growing number of cross-industry collaborations and partnerships 405.2.1.2 Need to control drug discovery & development costs and reduce time 415.2.1.3 Patent expiry 41 5.2.2 MARKET OPPORTUNITIES 425.2.2.1 Growing biotechnology industry 425.2.2.2 Emerging markets 425.2.3 MARKET CHALLENGES 425.2.3.1 Limited availability of data sets 426 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 436.1 INTRODUCTION 446.2 SOFTWARE 446.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING MARKET GROWTH 446.3 SERVICES 466.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 467 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 487.1 INTRODUCTION 497.2 MACHINE LEARNING 497.2.1 INCREASING ADOPTION OF ML BY RESEARCH CENTERS & PHARMACEUTICAL COMPANIES TO SUPPORT THE GROWTH OF THIS SEGMENT 497.2.2 DEEP LEARNING 517.2.3 SUPERVISED LEARNING 547.2.4 REINFORCEMENT LEARNING 567.2.5 UNSUPERVISED LEARNING 577.2.6 OTHER MACHINE LEARNING TECHNOLOGIES 597.3 OTHER TECHNOLOGIES 618 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 638.1 INTRODUCTION 648.2 IMMUNO-ONCOLOGY 648.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE IN THE SUPPLY OF CANCER DRUGS ARE THE KEY FACTORS DRIVING MARKET GROWTH 648.3 NEURODEGENERATIVE DISEASES 668.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT 668.4 CARDIOVASCULAR DISEASES 688.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING MARKET GROWTH 688.5 METABOLIC DISEASES 708.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT 708.6 OTHER APPLICATIONS 72 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 749.1 INTRODUCTION 759.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 759.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAVE DRAWN END-USER ATTENTION TO AI 759.3 CONTRACT RESEARCH ORGANIZATIONS 789.3.1 GROWING TREND OF OUTSOURCING PROVIDES SIGNIFICANT OPPORTUNITIES FOR CROS 789.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 809.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 8010 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 8210.1 INTRODUCTION 8310.2 NORTH AMERICA 8310.2.1.1 US 8610.2.1.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US 8610.2.1.2 Canada 8910.2.1.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support the market in Canada 8910.2.1.3 Mexico 9110.2.1.3.1 Government initiatives will support market growth in Mexico 9110.3 EUROPE 9210.3.1 UK 9510.3.1.1 The UK holds the largest share of the European market 9510.3.2 GERMANY 9810.3.2.1 Government support and favorable training programs are major market drivers in Germany 9810.3.3 FRANCE 9910.3.3.1 Strong government support and favorable strategies & initiatives form key drivers of the market in France 9910.3.4 REST OF EUROPE 10110.4 ASIA PACIFIC 10310.4.1

JAPAN 10510.4.1.1 Japan dominates the APAC market for AI in drug discovery 10510.4.2 CHINA 10610.4.2.1 Growing CMOs market and cross-industry collaborations are factors responsible for the growth of the market in China 10610.4.3 INDIA 10810.4.3.1 Steady adoption of AI technologies will drive market growth in India 10810.4.4 REST OF ASIA PACIFIC 11010.5 REST OF THE WORLD 11211 COMPETITIVE LANDSCAPE 11411.1 OVERVIEW 11411.2 MARKET SHARE ANALYSIS 11611.3 COMPETITIVE LEADERSHIP MAPPING 11711.3.1 VISIONARY LEADERS 11711.3.2 DYNAMIC DIFFERENTIATORS 11711.3.3 INNOVATORS 11711.3.4 EMERGING COMPANIES 11711.4 COMPETITIVE SITUATION AND TRENDS 11911.4.1 PRODUCT LAUNCHES AND ENHANCEMENTS 11911.4.2 EXPANSIONS 11911.4.3 ACQUISITIONS 12011.4.4 OTHER STRATEGIES 12012 COMPANY PROFILES 121(Business Overview, Products Offered, Recent Developments, MnM View)*12.1 MICROSOFT CORPORATION 12112.2 NVIDIA CORPORATION 12312.3 IBM CORPORATION 12512.4 GOOGLE (A SUBSIDIARY OF ALPHABET INC.) 12712.5 ATOMWISE, INC. 13012.6 DEEP GENOMICS 13212.7 CLOUD PHARMACEUTICALS, INC. 13312.8 INSILICO MEDICINE 13412.9 BENEVOLENTAI 13512.10 EXSCIENTIA 13612.11 CYCLICA 13812.12 BIOAGE 14012.13 NUMERATE 14112.14 NUMEDII, INC. 14212.15 ENVISAGENICS 14312.16 TWOXAR, INCORPORATED 14412.17 OWKIN, INC. 14512.18 XTALPI, INC. 14612.19 VERGE GENOMICS 14712.20 BERG LLC 148*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 13 APPENDIX 14913.1 DISCUSSION GUIDE 14913.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 15213.3 AVAILABLE CUSTOMIZATIONS 15413.4 RELATED REPORTS 15413.5 AUTHOR DETAILS 155

List Of Tables in Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

LIST OF TABLES

TABLE 1 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2017-2019) 40

TABLE 2 INDICATIVE LIST OF DRUGS LOSING PATENT IN 2019 41

TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,
2017-2024 (USD MILLION) 44

TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE,
BY REGION, 2017-2024 (USD MILLION) 45

TABLE 5 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY
COUNTRY, 2017-2024 (USD MILLION) 45

TABLE 6 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY,
2017-2024 (USD MILLION) 45

TABLE 7 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY,
2017-2024 (USD MILLION) 46

TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,
BY REGION, 2017-2024 (USD MILLION) 46

TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY,
2017-2024 (USD MILLION) 47

TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY,
2017-2024 (USD MILLION) 47

TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,
BY COUNTRY, 2017-2024 (USD MILLION) 47

TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY,
2017-2024 (USD MILLION) 49

TABLE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE,
2017-2024 (USD MILLION) 50

TABLE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION,
2017-2024 (USD MILLION) 50

TABLE 15 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 50

TABLE 16 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 51

TABLE 17 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 51

TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2017-2024 (USD MILLION) 52

TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 52

TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 53

TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 53

TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2017-2024 (USD MILLION) 54

TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 54

TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 55

TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 55

TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2017-2024 (USD MILLION) 56

TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 56

TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 57

TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 57

TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2017-2024 (USD MILLION) 58

TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 58

TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 58

TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017-2024 (USD MILLION) 59

TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING

TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION) 59

TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY,

2017-2024 (USD MILLION) 60

TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION) 60

TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION) 60

TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION) 61

TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION) 61

TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION) 62

TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION) 62

TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION,

2017-2024 (USD MILLION) 64

TABLE 43 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 65

TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2017-2024 (USD MILLION) 65

TABLE 45 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION) 65

TABLE 46 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION) 66

TABLE 47 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

IMMUNO-ONCOLOGY, BY COUNTRY, 2017-2024 (USD MILLION) 66

TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017-2024 (USD MILLION) 67

TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 67

TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 68

TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 68

TABLE 52 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 69

TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017-2024 (USD MILLION) 69

TABLE 54 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 69

TABLE 55 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 70

TABLE 56 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 70

TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2017-2024 (USD MILLION) 71

TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 71

TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 71

TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017-2024 (USD MILLION) 72

TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2024 (USD MILLION) 72

TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 73

TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 73

TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 73

TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER,
2017-2024 (USD MILLION) 75

TABLE 66 INDICATIVE LIST OF DEVELOPMENTS 76

TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017-2024 (USD MILLION) 76

TABLE 68 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017-2024 (USD MILLION) 77

TABLE 69 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017-2024 (USD MILLION) 77

TABLE 70 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2017-2024 (USD MILLION) 77

TABLE 71 INDICATIVE LIST OF COLLABORATIONS WITH CROS 78

TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2017-2024 (USD MILLION) 78

TABLE 73 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 79

TABLE 74 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 79

TABLE 75 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 79

TABLE 76 INDICATIVE LIST OF RESEARCH COLLABORATIONS 80

TABLE 77 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2017-2024 (USD MILLION) 80

TABLE 78 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION) 81

TABLE 79 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION) 81

TABLE 80 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, 2017-2024 (USD MILLION) 81

TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2017-2024 (USD MILLION) 83

TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 85

TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 85

TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 85

TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 86

TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2017-2024 (USD MILLION) 86

TABLE 87 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 87

TABLE 88 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 87

TABLE 89 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 88

TABLE 90 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 88

TABLE 91 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 88

TABLE 92 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 89

TABLE 93 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 90

TABLE 94 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 90

TABLE 95 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 90

TABLE 96 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 91

TABLE 97 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 91

TABLE 98 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 92

TABLE 99 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 92

TABLE 100 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 94

TABLE 101 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 94

TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 94

TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 95

TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY END USER, 2017-2024 (USD MILLION) 95

TABLE 105 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 96

TABLE 106 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD
MILLION) 96

TABLE 107 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD
MILLION) 97

TABLE 108 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD
MILLION) 97

TABLE 109 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD
MILLION) 97

TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY OFFERING, 2017-2024 (USD MILLION) 98

TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017-2024 (USD MILLION) 98

TABLE 112 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017-2024 (USD MILLION) 99

TABLE 113 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY END USER, 2017-2024 (USD MILLION) 99

TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY OFFERING, 2017-2024 (USD MILLION) 100

TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY TECHNOLOGY, 2017-2024 (USD MILLION) 100

TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY APPLICATION, 2017-2024 (USD MILLION) 100

TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD
MILLION) 101

TABLE 118 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD
MILLION) 101

TABLE 119 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD
MILLION) 102

TABLE 120 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD
MILLION) 102

TABLE 121 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD
MILLION) 102

| |
|--|
| TABLE 122 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 103 |
| TABLE 123 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 103 |
| TABLE 124 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 104 |
| TABLE 125 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 104 |
| TABLE 126 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 104 |
| TABLE 127 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 105 |
| TABLE 128 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 105 |
| TABLE 129 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 106 |
| TABLE 130 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 106 |
| TABLE 131 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 107 |
| TABLE 132 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 107 |
| TABLE 133 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 108 |
| TABLE 134 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 108 |
| TABLE 135 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 109 |
| TABLE 136 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 109 |
| TABLE 137 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 109 |
| TABLE 138 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 110 |
| TABLE 139 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 110 |
| TABLE 140 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 111 |
| TABLE 141 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, |

BY APPLICATION, 2017-2024 (USD MILLION) 111

TABLE 142 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 111

TABLE 143 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017-2024 (USD MILLION) 112

TABLE 144 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION) 112

TABLE 145 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017-2024 (USD MILLION) 113

TABLE 146 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017-2024 (USD MILLION) 113

TABLE 147 PRODUCT LAUNCHES AND ENHANCEMENTS, 2016-2019 119

TABLE 148 EXPANSIONS, 2016-2019 119

TABLE 149 ACQUISITIONS, 2016-2019 120

TABLE 150 OTHER STRATEGIES, 2016-2019 120

List Of Figures, Charts and Diagrams in Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immunology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

LIST OF FIGURES

FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION 18

FIGURE 2 RESEARCH DESIGN 21

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 25

FIGURE 4 BOTTOM-UP APPROACH 27

FIGURE 5 TOP-DOWN APPROACH 27

FIGURE 6 DATA TRIANGULATION METHODOLOGY 28

FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,

2019 VS. 2024 (USD MILLION) 30

FIGURE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2019-2024 31

FIGURE 9 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY APPLICATION,

2019 VS. 2024 (USD MILLION) 32

FIGURE 10 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY END USER,

2019 VS. 2024 (USD MILLION) 33

FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 34

FIGURE 12 NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A MAJOR FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS 35

FIGURE 13 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING

THE FORECAST PERIOD 36

FIGURE 14 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE

IN 2018 37

FIGURE 15 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI

IN DRUG DISCOVERY 38

FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 39

FIGURE 17 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 84

FIGURE 18 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 93

FIGURE 19 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES 114

FIGURE 20 MARKET EVOLUTION FRAMEWORK 115

FIGURE 21 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 116

FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE AI IN DRUG DISCOVERY MARKET 118

FIGURE 23 MICROSOFT CORPORATION: COMPANY SNAPSHOT 121

FIGURE 24 NVIDIA CORPORATION: COMPANY SNAPSHOT 123

FIGURE 25 IBM CORPORATION: COMPANY SNAPSHOT 125

FIGURE 26 ALPHABET: COMPANY SNAPSHOT 127

How to Buy...

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/237298>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4803** | Single User Price
- \$5653** | Multi User Price
- \$6928** | Corporate License Price
- \$8500** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.